Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial.

ABSTRACT:

Purpose

For patients with high-risk neuroblastoma (HR-NB), a dose of 21 Gy to the primary tumor site after gross total resection (GTR) provides excellent local control. However, no clinical trial has specifically evaluated the optimal dose of radiation therapy (RT), and RT-related long-term toxicities are of increasing concern. We sought to assess local control, survival outcomes, and toxicity after a reduction in dose to the primary site from 21 Gy to 18 Gy.

Methods and materials

After induction chemotherapy and GTR, patients with HR-NB were enrolled and treated on an RT dose-reduction prospective trial with 18 Gy hyperfractionated RT given in twice-daily fractions of 1.5 Gy each.

Results

The 25 study subjects were 1.6 to 9.5 (median, 4.3) years old at enrollment and

SUBMITTER: Casey DL 

PROVIDER: S-EPMC6499671 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature